NOVEL COMPOUND OF STEROCALPIN A FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS

PURPOSE: A composition for the prevention and treatment of arteriosclerosis containing a novel compound of stereocalpin-A is provided to suppress the expression of VCAM-1 and ICAM-1 induced by TNF-alpha due to the incapability of signal transduction to MAP kinse, Akt, and NF-kB by the suppression of the ROS production. CONSTITUTION: A pharmaceutical composition for the prevention and treatment of arteriosclerosis comprises stereocalpin-A represented by chemical formula 1 as an active ingredient. The stereocalpin-A represented by the chemical formula 1 is contained at 0.01-10 parts by weight based on 100 parts by weight of composition. The stereocalpin-A represented by chemical formula 1 suppresses the expression of cell adhesion molecules which induces the TNF-alpha. The cell adhesion molecules are ICAM-1 or VCAM-1. The stereocalpin-A is originated from Ramalina terebrata..

Medienart:

Patent

Erscheinungsjahr:

2018

Erschienen:

2018

Enthalten in:

Europäisches Patentamt - (2018) vom: 27. Sept. Zur Gesamtaufnahme - year:2018

Sprache:

Unbestimmt

Beteiligte Personen:

YIM JOUNG HAN [VerfasserIn]
KIM IL CHAN [VerfasserIn]
KIM DOC KYU [VerfasserIn]
HAN SE JONG [VerfasserIn]
LEE HYOUNG SEOK [VerfasserIn]
OH HYUN CHEOL [VerfasserIn]
PYO SUHK NEUNG [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

615
A61K
A61P
Che

Anmerkungen:

Source: www.epo.org (no modifications made), Last update posted on www.epo.org: 2018-09-27, Last updated: 2021-03-11

Patentnummer:

KR20130043995

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA00647246X